# Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/empagliflozin-an-sglt2-inhibitor-reduced-the-mortality-rate-after-acute/

## Facts

| Field | Value |
| --- | --- |
| Author Names | H Oshima,Takayuki Miki,Atsushi Kuno,Masashi Mizuno,Tatsuya Sato,Masaya Tanno,Toshiyuki Yano,Kei Nakata,Yukishige Kimura,Koki Abe,Wataru Ohwada,Tetsuji Miura |
| Citations | 129 |
| DOI | 10.1124/jpet.118.253666 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://jpet.aspetjournals.org/content/jpet/368/3/524.full.pdf |
| OpenAlex ID | https://openalex.org/W2904272813 |
| PMID | 30552292 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Masashi Mizuno](https://scholariq.org/researchers/masashi-mizuno/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.